Key result
Raloxifene significantly increased brachial arterial flow-mediated vasodilatation from 4.5% to 9.2% and decreased carotid intima-media thickness from 0.82 mm to 0.72 mm over 12 months in osteoporotic postmenopausal women.
Why the study?
Does raloxifene improve brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women?
Cohort (n=31)
No
Does raloxifene improve brachial arterial endothelial function, carotid wall thickness, and arterial stiffness in osteoporotic postmenopausal women?
Answers are grounded in this paper and cite their sources.
Raloxifene therapy for 12 months significantly improved brachial arterial endothelial function and reduced carotid intima-media thickness in osteoporotic postmenopausal women, suggesting potential cardiovascular benefits.
The beneficial effects of raloxifene, a selective estrogen receptor modulator, on cardiovascular risks and events have been investigated. Brachial arterial flow-mediated vasodilatation (FMD), carotid intima-media thickness (IMT), and pulse wave velocity (PWV) have been widely used in clinical settings as surrogate markers of atherosclerosis. This study investigated the simultaneous effects of raloxifene on brachial arterial FMD, carotid IMT, and PWV in osteoporotic postmenopausal women. A total of 31 postmenopausal women with osteoporosis or osteopenia were divided into 2 groups: a raloxifene group (n = 15; mean age +/- SD, 66.1 +/- 8.2 years) was treated with raloxifene hydrochloride (60 mg/day) orally for 12 months, and an untreated control group (n = 16; 64.1 +/- 7.8 years). Brachial arterial FMD, carotid IMT, and brachial-ankle PWV (baPWV) were measured at baseline and at 12 months after the start of the study. The brachial arterial FMD increased significantly, from 4.5 +/- 1.8% to 9.2 +/- 3.0%, in the raloxifene group (P < 0.01) but did not change in the control group. Nitroglycerin-induced vasodilatation did not change in either group. The carotid IMT decreased significantly, from 0.82 +/- 0.15 mm to 0.72 +/- 0.11 mm, in the raloxifene group (P < 0.01) but did not change in the control group. The baPWV did not change in either group. In conclusion, raloxifene may have beneficial effects on brachial arterial endothelial function and carotid wall thickness in osteoporotic postmenopausal women.
No takes yet. Share an insight, caveat, or question.
Sumino et al. (2010) conducted a cohort in Osteoporosis or osteopenia (n=31). Raloxifene hydrochloride vs. Untreated control group was evaluated on Brachial arterial flow-mediated vasodilatation (FMD) at 12 months (p=<0.01). Raloxifene significantly increased brachial arterial flow-mediated vasodilatation from 4.5% to 9.2% and decreased carotid intima-media thickness from 0.82 mm to 0.72 mm over 12 months in osteoporotic postmenopausal women.
Synapse has enriched 10 related papers. Consider them for comparative context: